Smoking and perioperative effects along with current recommendations for pre operative cessation
Reading File
Finding Sources
Finding Sources
Searching PubMed
smoking cessation preoperative perioperative outcomes
Reading File
Reading File
Reading File
Reading Article
PMID: 40840082
Reading Article
PMID: 40053349
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Let me compile the full, detailed answer.
Smoking and Perioperative Effects: Mechanisms, Complications, and Cessation Recommendations
1. Why Smoking Matters Perioperatively
Tobacco smoke contains more than 4,000 compounds. Three are of primary perioperative concern:
- Nicotine - activates nicotinic receptors in vascular smooth muscle causing vasoconstriction, tachycardia, and hypertension; impairs microvascular perfusion; raises myocardial oxygen demand
- Carbon monoxide (CO) - binds haemoglobin with 200x the affinity of oxygen, forming carboxyhaemoglobin (COHb 10-15% in active smokers), which shifts the oxyhaemoglobin dissociation curve left and reduces tissue oxygen delivery
- Hydrogen cyanide - impairs mitochondrial oxidative metabolism
Barash Clinical Anesthesia 9e, p. 86 | Maingot's Abdominal Operations, p. 34
2. Perioperative Complications by System
Pulmonary
Smoking is the most important modifiable pulmonary risk factor. It causes:
- Mucociliary dysfunction and hypersecretion - secretions accumulate, raising atelectasis and pneumonia risk
- Airway hyperreactivity - increased susceptibility to laryngospasm and bronchospasm on intubation
- Structural COPD in long-term smokers - reduced FEV1, air trapping
- Impaired surfactant production and mucociliary clearance (compounded by volatile anaesthetics)
Even without pre-existing lung disease, smoking confers a relative risk of 1.4-4.3 for perioperative pulmonary complications. There is a dose-dependent effect: >20 pack-years substantially increases risk of pulmonary complications. Respiratory infections, prolonged mechanical ventilation, and reintubation are all more frequent. Postoperative pulmonary complications contribute to marginally higher inpatient costs (relative cost 1.04, 95% CI 1.00-1.07 compared with never-smokers).
Barash 9e, p. 86 | Sabiston Textbook of Surgery 21e, p. 86 | Maingot's, p. 34
Cardiovascular
Nicotine increases heart rate, blood pressure, and myocardial oxygen consumption while simultaneously causing vasoconstriction that reduces coronary perfusion. CO reduces oxygen-carrying capacity. Together, these worsen the supply-demand balance and increase perioperative myocardial ischaemia risk.
Wound Healing and Surgical Site Infection
Nicotine-mediated vasoconstriction reduces tissue oxygen tension in wound beds - a major driver of wound complications. Smoking is associated with:
- Postoperative wound disruption: OR 1.65 (95% CI 1.56-1.75)
- Surgical site infection: OR 1.31 (95% CI 1.28-1.34)
Many toxic compounds in cigarette smoke impair fibroblast function and collagen synthesis, further delaying healing.
Sabiston 21e, p. 86
Immunological
Chronic tobacco exposure suppresses immune function. This includes impaired neutrophil and macrophage activity, contributing to both infectious complications and delayed wound repair.
3. Timeline of Benefits After Cessation
The benefits of cessation are time-dependent and occur progressively:
| Time After Quitting | Physiological Change |
|---|---|
| 12-24 hours | COHb levels fall to those of non-smokers; improved oxygen delivery begins |
| 48-72 hours | Mucociliary clearance starts improving; cyanide levels fall; nicotine levels decrease, allowing vasodilatation |
| 2-4 weeks | Tissue microenvironment improves; reversal of smoking effects on inflammatory cellular function; wound healing risk begins to decline |
| 4-8 weeks | Significant reduction in pulmonary complication risk; sputum production normalises; mucous clearance substantially improved |
| >8 weeks | Maximum benefit for both pulmonary and wound healing outcomes |
Miller's Anesthesia 10e, p. 3955-3956 | Maingot's, p. 34 | Mulholland Surgery 7e, p. 915
The key point on early quitters: An early study raised concerns about increased airway reactivity in patients who quit within 8 weeks ("paradoxical increase"), but subsequent systematic reviews have found no increased risk of adverse events with quitting soon before surgery (i.e., within 8 weeks). Motivated patients should be encouraged to quit at any point before surgery.
Miller's Anesthesia 10e, p. 3956
4. Quantified Risk Reduction with Preoperative Cessation
Meta-analysis data (Morgan & Mikhail, 2023):
Preoperative smoking cessation for any type of surgery reduces postoperative complications by 41%, especially those related to wound healing and pulmonary complications.
2025 Systematic Review and Meta-Analysis (Tang et al., J Clin Anesth 2025 - PMID 40840082):
55 studies included. Key findings for reduction in complications versus active smokers:
| Cessation Duration | Pulmonary Complications | Wound Complications | Composite Complications | Mortality |
|---|---|---|---|---|
| ≥2 weeks | -27% (RR 0.73) | - | - | - |
| ≥4 weeks | -29% (RR 0.71) | -33% (RR 0.67) | -31% (RR 0.69) | -14% (RR 0.86) |
| ≥8 weeks | -37% (RR 0.63) | - | - | - |
Short-term cessation did not significantly reduce surgical site infections or bleeding in this analysis.
2025 Cancer Surgery Meta-Analysis (Wong et al., JAMA Network Open 2025 - PMID 40053349):
Across 39,499 patients in 24 studies:
- Smoking within 4 weeks preoperatively vs. cessation ≥4 weeks: OR 1.31 (95% CI 1.10-1.55) for postoperative complications
- Current smokers vs. never-smokers: OR 2.83 (95% CI 2.06-3.88)
5. Current Recommendations for Preoperative Cessation
Timing
- Optimal minimum: 4-8 weeks before surgery is the widely cited target for both pulmonary and wound healing benefits
- Maximum benefit: >8 weeks; benefits of abstinence are realised progressively over the first year after cessation
- Any duration is better than none: surgery is a "teachable moment" - patients should be encouraged to quit even days before the procedure, as CO and cyanide levels fall rapidly within 24-48 hours
Morgan & Mikhail 7e, p. 2102 | Mulholland 7e, p. 915 | Murray & Nadel, p. 2722 | Miller's Anesthesia 10e, p. 3955
Framework: The "5 A's" Model
All perioperative providers should use the structured 5 A's framework (endorsed by Murray & Nadel and multiple perioperative guidelines):
- Ask - screen all patients for tobacco use at every preoperative visit
- Advise - give a clear, personalised recommendation to quit
- Assess - determine willingness and readiness to quit
- Assist - provide behavioral support and pharmacotherapy
- Arrange - set a quit date, schedule follow-up, connect with cessation programs
Pharmacological Interventions
- Nicotine Replacement Therapy (NRT) - patches, gum, or lozenges; first-line; does not increase perioperative risk; can be combined with counselling. Note: NRT patches during the perioperative period remain controversial in patients at risk for poor wound healing because nicotine itself (not just smoke) causes vasoconstriction
- Varenicline - should be started at least 1 week before an attempt at quitting; associated with increased long-term abstinence and does not increase perioperative risk; recommended by Miller's as a primary pharmacological option
- Bupropion - role in perioperative cessation remains unclear
- E-cigarettes/vaporised nicotine - their role and perioperative risk are still unknown and cannot be endorsed
Miller's Anesthesia 10e, p. 3955 | Murray & Nadel, p. 2724
Intensity of Intervention
Intensive multicomponent interventions are more effective than brief ones. Components include:
- Health professional visits
- Psychoeducational support (motivational interviewing)
- Pharmacotherapy
Weekly preoperative counseling + NRT may extend perioperative cessation to long-term success. A Cochrane review confirmed brief and intensive interventions both reduce perioperative smoking, with intensive programs being superior for long-term outcomes.
Morgan & Mikhail 7e, p. 2102 | Mulholland 7e, p. 915
Specific Guideline Sources
Detailed evidence-based guidance is available from:
- Society for Perioperative Assessment and Quality Improvement (SPAQI)
- French Society of Anesthesia and Resuscitation (SFAR)
- These are specifically referenced in Miller's Anesthesia 10e as the most current perioperative-specific cessation guidelines
Miller's Anesthesia 10e, p. 3955
6. Practical Clinical Takeaways
| Clinical Scenario | Recommendation |
|---|---|
| Elective surgery, smoker presenting months ahead | Target ≥8 weeks cessation; start NRT + counselling immediately |
| Elective surgery, smoker at preadmission clinic (3-4 weeks out) | Still valuable - ≥4 weeks reduces pulmonary, wound, and mortality risk; refer for intensive counselling |
| Smoker presenting <2 weeks before surgery | Do not cancel - encourage immediate cessation; CO clears within 24h; any benefit is worth pursuing |
| Patient concerned that "recent quitting makes things worse" | Reassure: systematic reviews show no increased risk of adverse events with cessation within 8 weeks |
| Post-op opportunity | Continue cessation support - perioperative interventions can achieve nicotine dependence reduction of up to 1 year |
Recent evidence update: The 2025 meta-analyses by Tang et al. (PMID 40840082) and Wong et al. (PMID 40053349) are fully consistent with textbook recommendations - both confirm that ≥4 weeks of cessation offers meaningful, quantifiable reductions in pulmonary complications, wound complications, composite complications, and mortality, with progressively better outcomes for longer cessation periods.
This is a shared conversation. Sign in to Orris to start your own chat.